Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women: A Therapeutic Advance But Many Unresolved Questions

DSpace/Manakin Repository

Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women: A Therapeutic Advance But Many Unresolved Questions

Citable link to this page

 

 
Title: Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women: A Therapeutic Advance But Many Unresolved Questions
Author: Ligibel, Jennifer A.; Winer, Eric Paul

Note: Order does not necessarily reflect citation order of authors.

Citation: Ligibel, Jennifer A., and Eric P. Winer. 2005. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Research 7(6): 255-257.
Full Text & Related Files:
Abstract: Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently available suggest that the aromatase inhibitors are efficacious either as upfront therapy or after a course of tamoxifen. Ongoing trials will compare these approaches and guide the use of these agents in the years to come.
Published Version: doi:10.1186/bcr1347
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410766/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8480660
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters